Newsfeeds - Spark Newswire

5 minute read

Psyched: Hawaii And Minnesota’s Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry’s Future And More

Today, 4:59 AM

Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and psilocybin as an alternative to treat mental health conditions.

AGNPF

1 minute read

Development Of DMT Transdermal Patch With Eye Disease Treatment In Mind

By Lara Goldstein

Today, 4:59 AM

Specialty R&D psychedelics company PharmaDrug Inc. (OTCQB: LMLLF) has inked a research collaboration agreement with PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) to evaluate the delivery of DMT through PharmaTher's microneedle patch technology.

LMLLF

1 minute read

PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation

By Lara Goldstein

Today, 4:59 AM

Specialty ketamine company PharmaTher Holdings Ltd.

PHRRF

5 minute read

Psyched: Australia Legalizes Psychedelics Therapy, BC’s Decrim, State Bills, Millions For Trials & Clinics

By Lara Goldstein

Today, 4:59 AM

Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically authorized psychiatrists to treat certain mental health conditions, such as post-traumatic stress disorder and psilocybin for treatment-resistant depression.

CSE:ORIG

3 minute read

PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch

By Lara Goldstein

Today, 4:59 AM

Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.

PHRRF

4 minute read

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More

By Lara Goldstein

Today, 4:59 AM

Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?

CLABF

2 minute read

Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News

By Lara Goldstein

Today, 4:59 AM

Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”

MSSTF

2 minute read

Psychedelics Market Could Reach $12B By 2029, Says New Report

By Lara Goldstein

Today, 4:59 AM

A new analysis of the global market for psychedelics performed by Brandessence Market Research shows an expected growth from 2022’s $4.87 billion to an annual valuation of nearly $12 billion before 2030.

CMPS

2 minute read

FDA OKs Ketamine For Treating Organ Transplant Injuries With ‘Orphan Drug’ Status

By Lara Goldstein

Today, 4:59 AM

The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. (OTCQB: PHRRF) an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation.

PHRRF

2 minute read

Ketamine for Parkinson’s Disease, PharmaTher Holdings Announces Grant of U.S. Patent To Cover It

By Joana Scopel

Today, 4:59 AM

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a pharmaceutical company focused on developing novel uses and delivery forms of ketamine

CSE:PHRM